

Piperonyl butoxide enhances triclabendazole action against triclabendazole-resistant *Fasciola hepatica*

C. DEVINE¹, G. P. BRENNAN¹, C. E. LANUSSE², L. I. ALVAREZ², A. TRUDGETT¹, E. HOEY¹ and I. FAIRWEATHER^{1*}

¹Parasite Therapeutics Group, School of Biological Sciences, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland

²Laboratorio de Farmacología, Departamento de Fisiopatología, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Campus Universitario (UNCPBA), 7000 Tandil, Argentina

(Received 20 June 2010; revised 1 July 2010; accepted 2 July 2010; first published online 15 October 2010)

SUMMARY

A study has been carried out to determine whether the action of triclabendazole (TCBZ) against the liver fluke, *Fasciola hepatica* is altered by inhibition of the cytochrome P450 (CYP 450)-mediated drug metabolism pathway. The Oberon TCBZ-resistant and Cullompton TCBZ-susceptible fluke isolates were used for these experiments, the basic design of which is given in the paper by Devine *et al.* (2010a). Piperonyl butoxide (PB) was the CYP 450 inhibitor used. Morphological changes resulting from drug treatment and following metabolic inhibition were assessed by means of transmission electron microscopy. After treatment with either TCBZ or TCBZ.SO on their own, there was greater disruption to the TCBZ-susceptible than TCBZ-resistant isolate. However, co-incubation with PB+TCBZ, but more particularly PB+TCBZ.SO, led to greater changes to the TCBZ-resistant isolate than with each drug on its own, with blebbing of the apical plasma membrane, severe swelling of the basal infolds and their associated mucopolysaccharide masses in the syncytium and flooding in the internal tissues. Golgi complexes were greatly reduced or absent in the tegumental cells and the synthesis and production of secretory bodies were badly disrupted. The mitochondria were swollen throughout the tegumental system and the somatic muscle blocks were disrupted. With the TCBZ-susceptible Cullompton isolate, there was a limited increase in drug action following co-incubation with PB. The results provide evidence that the condition of a TCBZ-resistant fluke can be altered by inhibition of drug metabolism. Moreover, they support the concept that altered drug metabolism contributes to the mechanism of resistance to TCBZ.

Key words: *Fasciola hepatica*, liver fluke, triclabendazole resistance, piperonyl butoxide, transmission electron microscopy.

INTRODUCTION

This investigation is part of a wider programme examining the role of altered drug metabolism in the development of resistance of *Fasciola hepatica* to triclabendazole (TCBZ). Biochemical studies have demonstrated that the flavin monooxygenase (FMO) and cytochrome P450 (CYP 450) enzyme pathways are involved in the metabolism of TCBZ by the fluke and are upregulated in TCBZ-resistant flukes (Mottier *et al.* 2004; Robinson *et al.* 2004; Alvarez *et al.* 2005). Complementary scanning electron microscope (SEM) studies have shown that co-incubation of TCBZ or its sulphoxide metabolite with metabolic inhibitors, such as methimazole (MTZ), piperonyl butoxide (PB) and ketoconazole (KTZ), leads to greater surface disruption of TCBZ-resistant than TCBZ-susceptible flukes (Devine *et al.* 2009, 2010a, c). This article is a follow-on from the previous SEM paper with PB (Devine *et al.* 2010a). It

examines internal changes to the tegument of the fluke, as visualized by transmission electron microscopy (TEM). While surface changes represent the sum of a number of drug effects, TEM will be more informative with regard to the mechanisms contributing to them and thus will extend understanding of drug action. PB is an established CYP 450 inhibitor and it has been shown to inhibit the metabolism of TCBZ by *F. hepatica* (Alvarez *et al.* 2005).

MATERIALS AND METHODS

The protocol for this investigation is the same as that used for the SEM study involving PB (Devine *et al.* 2010a); the reader is referred to that publication for full details. Briefly, adult flukes of the Cullompton TCBZ-susceptible and the Oberon TCBZ-resistant fluke isolates were pre-incubated in PB at a concentration of 1×10^{-4} M for 2 h at 37 °C, before transfer to fresh NCTC 135 culture medium for 22 h at 37 °C. The fresh medium contained either PB; PB+NADPH (1 nM); PB+NADPH+TCBZ (15 µg/ml); or PB+NADPH+TCBZ.SO (15 µg/ml). A stock solution of PB was initially prepared at a

* Corresponding author: School of Biological Sciences, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland. Tel: +44 28 90972298. Fax: +44 28 90975877. E-mail: i.fairweather@qub.ac.uk

concentration of 1×10^{-1} M in methanol. Controls at 0 h and 24 h were also prepared. After incubation, the flukes were fixed and processed for transmission electron microscopy (TEM), as described by Devine *et al.* (2010b). A minimum of 4 flukes were prepared for each treatment.

RESULTS

After incubation in all drug and inhibitor combinations for 24 h *in vitro*, the flukes were alive prior to fixation. Sections for TEM were taken from the midbody region of the flukes as this area was shown to be highly affected by drug and inhibitor action in a previous SEM study (Devine *et al.* 2010a).

Controls

The tegumental ultrastructure of the control specimens was normal. For images of normal morphology, the reader is referred to the papers by Halferty *et al.* (2009, Fig. 4A–C) and Fairweather *et al.* (1999, Figs 3.3 and 3.4).

Oberon and *Cullompton* isolates treated with PB and PB + NADPH

The tegumental syncytium retained a relatively normal morphology (Fig. 1A). Below the apical plasma membrane, T1 and T2 secretory bodies were present and existed in normal numbers (Fig. 1B). There was some swelling of the mucopolysaccharide masses surrounding the basal infolds in the basal region of the syncytium (Fig. 1C). The muscle blocks below the basal lamina remained unchanged (Fig. 1C). Within the tegumental cells, there were numerous T1 secretory bodies (Fig. 1D). The cells also contained numerous active and well-developed Golgi complexes and the nuclei and mitochondria retained a normal morphology (Fig. 1D and 1E).

Cullompton isolate treated with TCBZ and TCBZ.SO

Descriptions of ultrastructural changes brought about by treatment with the two drugs have been published elsewhere and will not be repeated here. The changes observed in the present study matched these descriptions. Therefore, the reader is referred to the paper by Halferty *et al.* (2009) (Fig. 4D–F for TCBZ and Fig. 5A–C for TCBZ.SO).

Cullompton isolate treated with PB + NADPH + TCBZ

Within the tegumental syncytium, mild swelling of the mucopolysaccharide masses surrounding the basal infolds was observed (Fig. 2A). In the apical region, T1 and T2 secretory bodies were present in

normal numbers. The mitochondria present throughout the syncytium were swollen and rounded, with distinct cristae (Fig. 2B and C). There was some swelling of the mucopolysaccharide masses in the basal region, although the basal infolds remained tightly closed. Numerous T1 secretory bodies were present at the base of the syncytium (Fig. 2C). Within Type-1 tegumental cells, T1 secretory bodies were abundant and Golgi complexes were present (Fig. 2D and E). The mitochondria and cisternae of the granular endoplasmic reticulum (GER) were swollen (Fig. 2D). Within the Type-2 tegumental cells, the nucleus and mitochondria appeared relatively normal, and numerous T2 secretory bodies were present (Fig. 2F).

Cullompton isolate treated with PB + NADPH + TCBZ.SO

The tegumental syncytium appeared relatively normal, with only very minor swelling of the mucopolysaccharide masses (Fig. 3A). In the apical region of the tegument, T1 and T2 secretory bodies were present in normal numbers (Fig. 3B). Swelling of the mucopolysaccharide masses was most evident in the basal region of the syncytium, although the membranes of the basal infolds were tightly apposed. T1 secretions were abundant throughout the basal region and the mitochondria present throughout the syncytium were swollen and rounded in appearance (Fig. 3C). There was evidence of spacing between tegumental cells (Fig. 3D). The tegumental cells contained numerous T1 secretory bodies and some Golgi complexes were present, but appeared reduced in size. The nuclei appeared normal but many mitochondria were swollen and rounded in appearance (Fig. 3D).

Oberon isolate treated with TCBZ

Descriptions of ultrastructural changes brought about by drug treatment have been published elsewhere and will not be repeated here. The changes observed in the present study matched these descriptions. Therefore, the reader is referred to the paper by Devine *et al.* (2010b) (Figs 12–16).

Oberon isolate treated with TCBZ.SO

The changes to the tegumental syncytium following incubation in TCBZ.SO have been described by McKinstry (2008; Chapter 7, Figs 15–20) and will not be repeated in detail here. A brief summary has been given by Devine *et al.* (2010b).

Oberon isolate treated with PB + NADPH + TCBZ

Minimal changes were observed within the tegumental syncytium. Swelling of the mucopolysaccharide




Fig. 1. Transmission electron micrographs (TEMs) of the tegumental syncytium, underlying musculature and tegumental cells of adult *Fasciola hepatica* (Cullompton and Oberon isolates) treated *in vitro* with PB and PB+NADPH for 24 h. (A) TEM showing the full depth of the tegumental syncytium, from the apical plasma membrane (APM) to the basal lamina (BL). The muscle blocks (Mu) beneath the basal lamina, like the syncytium, retain a normal morphology. m, mitochondrion. (B) A high-power micrograph of the apical region of the tegumental syncytium. Numerous T1 (T1) and T2 (T2) secretory bodies are present below the apical plasma membrane (APM). m, mitochondrion. (C) Basal region of the tegumental syncytium, showing swelling of the mucopolysaccharide masses (arrow). T1 (T1) and T2 (T2) secretory bodies are present in the syncytium. Below the basal lamina (BL), the muscle blocks (Mu) retain a normal morphology. BI, basal infolds; m, mitochondrion. (D) TEM of a T1-type of tegumental cell. Well-developed Golgi complexes (GC) and numerous T1 secretory bodies (T1) are present within the cell. The mitochondria (m) retain a relatively normal morphology. N, nucleus. (E) A high-power image of a well-developed Golgi complex (GC). T1 secretory bodies (T1) are present within the cell and the mitochondria (m) retain a relatively normal morphology.




Fig. 2. Transmission electron micrographs (TEMs) of the tegumental syncytium, underlying musculature and tegumental cells of adult *Fasciola hepatica* (Cullompton isolate) following 24 h *in vitro* treatment with PB + NADPH + TCBZ. (A) TEM showing the full depth of the tegumental syncytium, from the apical plasma membrane (APM) to the basal lamina (BL). Some swelling of the mucopolysaccharide masses (arrow) can be seen in the basal region. m, mitochondrion. (B) A high-power micrograph of the apical region of the syncytium. Numerous T1 (T1)




Fig. 3. Transmission electron micrographs (TEMs) of the tegumental syncytium, underlying musculature and tegumental cells of adult *Fasciola hepatica* (Cullompton isolate) following *in vitro* treatment for 24 h with PB + NADPH + TCBZ.SO. (A) TEM showing the full depth of the tegumental syncytium, from the apical plasma membrane (APM) to the basal lamina (BL). The mitochondria (m) in the syncytium are rounded in appearance. Slight swelling of the mucopolysaccharide masses (arrow) can be seen above the basal lamina, although the basal infolds (BI) remain tightly closed. (B) A high-power micrograph of the apical region of the tegumental syncytium. Numerous T1 (T1) and T2 (T2) secretory bodies are present below the apical plasma membrane (APM). (C) TEM showing the basal region of the syncytium. Above the basal lamina (BL), the mucopolysaccharide masses (arrow) are swollen, but the basal infolds (BI) remain closed. The mitochondria (m) appear slightly swollen. T1, T1 secretory bodies. (D) TEM showing T1-type tegumental cells. There is spacing between the cells (arrows). T1 secretory bodies (T1) are abundant in number within the cells, but Golgi complexes (GC) appear reduced in size. Some mitochondria (m) have become swollen in appearance. The nuclei (N) of the cells retain a normal morphology.

and T2 (T2) secretory bodies are present below the apical plasma membrane (APM). The mitochondria (m) are swollen with distinct cristae (arrow). (C) TEM showing the basal region of the syncytium. The mucopolysaccharide masses (arrow) are slightly swollen just above the basal lamina (BL). The mitochondria (m) are swollen and rounded in appearance. Numerous T1 (T1) secretory bodies are present. BI, basal infolds. (D) TEM showing a T1-type of tegumental cell. There are many T1 secretory bodies (T1) in the cell; Golgi complexes (GC) are also present. Some mitochondria (m) are swollen in appearance, as are the cisternae of the granular endoplasmic reticulum (arrow). (E) A high-power micrograph of a Golgi complex (GC), which retains a normal morphology. N, nucleus. (F) A high-power TEM of a T2-type of tegumental cell. T2 (T2) secretory bodies are present within the cell. The mitochondria (m) present within the cell retain a relatively normal morphology. N, nucleus.




Fig. 4. Transmission electron micrographs (TEMs) of the tegumental syncytium, underlying musculature and tegumental cells of adult *Fasciola hepatica* (Oberon) isolate treated *in vitro* for 24 h with PB+NADPH+TCBZ. (A) TEM of the tegumental syncytium, showing limited swelling of the mucopolysaccharide masses (arrows) at the

masses was limited, although the mitochondria present within the syncytium appeared swollen (Fig. 4A). Small blebs were present along the apical plasma membrane (Fig. 4B). T1 and T2 secretory bodies were present but were abnormal, in that they appeared swollen and electron-lucent (Fig. 4B). The basal infolds above the basal lamina were swollen at their bases (Fig. 4C). Below the tegumental syncytium, the fibres of the muscle blocks appeared more loosely-packed than normal (Fig. 4D). Within the T1-type tegumental cells, T1 secretory bodies were present within the cells, although their numbers were severely reduced and Golgi complexes, if present, were reduced in size (Fig. 4E). The mitochondria and the cisternae of the GER were swollen, but the nuclei retained a normal appearance (Fig. 4E). T2 secretory bodies were present within Type-2 tegumental cells, although they were few in number (Fig. 4F). The mitochondria were swollen, with distinct cristae, and the cisternae of the GER were also swollen (Fig. 4F).

Oberon isolate treated with PB + NADPH + TCBZ.SO

The major feature of the tegumental syncytium was the severe swelling of the basal infolds, accompanied by swelling of the mucopolysaccharide masses surrounding them (Fig. 5A). Along the apex of the syncytium, blebbing of the tegumental surface was observed (Fig. 5B). At higher magnifications, microvillus-like projections were seen along the apical plasma membrane (Fig. 5C). T1 and T2 secretory bodies were present within the syncytium, but appeared swollen and electron-lucent (Fig. 5C). The mitochondria present within the syncytium were swollen and assumed a rounded appearance, rather than the typical cylindrical shape (Fig. 5D). The sub-tegumental muscle blocks contained fewer fibres than normal and the fibres were less tightly packed than normal (Fig. 5D). Spaces were observed between the tegumental cells. T1 and T2 secretory bodies were present in their respective tegumental cells, although the number of secretory bodies was

fewer than normal in both cell types (Fig. 5E and F). Within the Type-1 tegumental cells, the T1 secretory bodies appeared swollen and were severely reduced in number (Fig. 5E). Golgi complexes were not observed in the cells. The mitochondria were swollen, with distinct cristae, but the nuclei retained a normal appearance (Fig. 5E). In the Type-2 tegumental cells, the perinuclear space between the inner and outer nuclear membranes was enlarged (Fig. 5F). Within both cell types, the cisternae of the GER were swollen (Fig. 5E and F).

The main changes brought about by drug action and the relative severity of the changes are summarized in Tables 1 and 2.

DISCUSSION

The results of this study have shown that co-administration of PB, a CYP 450 inhibitor, with either TCBZ or TCBZ.SO can potentiate drug action against the TCBZ-resistant Oberon isolate of *Fasciola hepatica*. While treatment with TCBZ or TCBZ.SO alone resulted in more severe disruption to the TCBZ-susceptible Cullompton isolate, co-treatment with PB did not enhance the action of either drug against this isolate.

Incubation in PB alone or PB + NADPH caused limited disruption to the ultrastructure of both fluke isolates. Very minor swelling of the mucopolysaccharide masses associated with the basal infolds, was observed in a few specimens but this was a limited phenomenon. The syncytium of the Oberon isolate treated with TCBZ alone retained a relatively normal morphology. Only limited swelling of the mucopolysaccharide masses and mitochondria within the syncytium was observed. 'Open' bodies were present at the apex of the syncytium. They occur in a stress situation, such as that induced by drug action, and are caused by the accelerated release of secretory bodies from the tegumental surface (Rogan and Threadgold, 1984). Within the tegumental cells, numerous secretory bodies and active Golgi complexes were observed, indicating that the production of the secretory bodies had not been disrupted. When

distal ends of the basal infolds (BI). The mitochondria (m) appear slightly swollen. APM, apical plasma membrane. (B) High-power micrograph of the apical region of the tegument showing blebs (B) on the apical plasma membrane (APM). Numerous T1 (T1) and T2 (T2) secretory bodies are present within this region, but appear swollen and electron-lucent. (C) TEM showing the basal region of the tegumental syncytium. Above the basal lamina (BL), the amino mucopolysaccharide masses (arrow) are swollen. The mitochondria (m) are also swollen. BI, basal infolds. (D) TEM showing the basal region of the tegumental syncytium and the underlying muscle blocks (Mu). The muscle fibres in the muscle blocks (Mu) are not as tightly-packed as normal. BL, basal lamina. (E) TEM showing a T1-type of tegumental cell. The Golgi complexes (GC) present in the cell appear abnormal in shape and reduced in size. T1 (T1) secretory bodies are reduced in number within the cell. The cisternae of granular endoplasmic reticulum (arrow) are severely swollen and the mitochondria (m) are swollen and rounded in appearance. The nucleus (N) retains a normal morphology. Inset shows a Golgi complex (GC) which is reduced in size. (F) A high-power TEM of a T2-type of tegumental cell. A small number of T2 (T2) secretory bodies are present within the cell. The mitochondria (m) are rounded with swollen cristae (arrow). N, nucleus.




Fig. 5. Transmission electron micrographs (TEMs) of the tegumental syncytium, underlying musculature and tegumental cells of adult *Fasciola hepatica* (Oberon) isolate treated *in vitro* for 24 h with PB+NADPH+TCBZ.SO. (A) TEM showing the full depth of the tegumental syncytium from the apical plasma membrane (APM) to the

Table 1. Oberon isolate of *Fasciola hepatica*. Summary of changes to the tegumental system following different drug treatments

Disruption	Treatment					
	PB	PB+NADPH	TCBZ	PB+NADPH+TCBZ	PB+NADPH+TCBZ.SO	TCBZ.SO
<i>Changes in Syncytium</i>						
Blebbing	–	–	–	+	++	+
Microvillus-like projections	–	–	–	–	+	–
Presence of 'open' bodies	–	–	+	–	–	+
Altered numbers of secretory bodies at apex	–	–	–	–	–	+
Swelling of basal infolds	–	–	–	–	+++	–
Swelling of mucopolysaccharide masses	+	+	+	+	+++	+
Swelling of mitochondria	–	–	+	+	++	+
Disruption to muscle fibres	–	–	–	+	+	–
<i>Changes in Tegumental Cells</i>						
Reduction in number of secretory bodies	–	–	+	++	++	–
Reduction in number and size of Golgi complexes	–	–	–	++	+++	+
Swelling of cisternae of GER	–	–	+	++	++	–
Swelling of mitochondria	–	–	+	++	++	–
Spacing between cells	–	–	–	–	+	–
Total	1	1	6	12	22	6

–, No noticeable disruption; +, general/mild disruption; ++, severe disruption; +++, very severe disruption. PB, piperonyl butoxide; NADPH, nicotinamide adenine dinucleotide phosphate; TCBZ, triclabendazole; TCBZ.SO, triclabendazole sulphoxide; GER, granular endoplasmic reticulum.

TCBZ was co-incubated with PB, blebbing was observed along the apical plasma membrane of the Oberon isolate. Blebbing is a stress response to drug treatment: it is a survival mechanism for shedding surface membrane damaged by drug action. It has been observed in a number of studies using fasciolicides (Stitt and Fairweather, 1993; Buchanan *et al.* 2003; Mc Kinstry *et al.* 2003; Meaney *et al.* 2003, 2004, 2006; Walker *et al.* 2004). T1 and T2 secretory bodies were present in the apical region of the syncytium in relatively normal numbers, but appeared abnormal in that they were swollen and electron-lucent. The fibres within the muscle blocks appeared more loosely packed than those seen in

control specimens. Production of secretory bodies in the tegumental cells appeared to be affected, as indicated by the reduced size and number of Golgi complexes and the reduced number and abnormality of the secretory bodies. In addition, swelling of the mitochondria and the cisternae of GER was greater following co-incubation of TCBZ with PB.

Treatment of the Oberon isolate with TCBZ.SO led to a similar level of disruption as that induced by TCBZ. However, co-incubation with PB led to a dramatic increase in the degree of disruption observed. The major altered feature of the tegumental syncytium was the severe swelling of the basal infolds and their associated mucopolysaccharide masses,

basal lamina (BL). The basal infolds (BI) are severely swollen and swelling of the mucopolysaccharide masses (arrow) at the proximal end can also be seen. Mitochondria (m) are present throughout the syncytium, but appear slightly swollen. (B) A high-power micrograph of the apex of the tegumental syncytium. Blebbing (B) of the apical plasma membrane (APM) is evident and the mucopolysaccharide masses are slightly swollen (arrow) towards the distal end of the basal infolds (BI). (C) High-power micrograph of the apical region of the tegument showing microvillus-like projections (MV) and blebbing (B) along the apical plasma membrane. T1 (T1) and T2 (T2) secretory bodies are present within this region and appear swollen and electron-lucent. (D) TEM showing the basal region of the tegumental syncytium. Above the basal lamina (BL), the basal infolds (BI) are severely swollen. The mitochondria (m) are also swollen. The fibres within the subtegumental muscle blocks (Mu) are fewer and appear more loosely packed than normal. (E) TEM showing a T1-type of tegumental cell. A small number of swollen T1 (T1) secretory bodies can be seen within the cell. The mitochondria (m) are rounded with swollen cristae (arrow) and the cisternae of granular endoplasmic reticulum (double arrow) are severely swollen. The nucleus (N) appears normal. (F) A high-power TEM of a T2-type of tegumental cell. A small number of T2 (T2) secretory bodies are present within the cell. The perinuclear space around the nucleus is swollen (arrow).

Table 2. Cullompton isolate of *Fasciola hepatica*. Summary of changes to the tegumental system following different drug treatments

	Treatment					
	PB	PB+NADPH	TCBZ	PB+NADPH+TCBZ	PB+NADPH+TCBZ.SO	TCBZ.SO
<i>Changes in Syncytium</i>						
Blebbing	–	–	–	–	–	–
Microvillus-like projections	–	–	–	–	–	–
Presence of 'open' bodies	–	–	–	–	–	–
Altered numbers of secretory bodies within the syncytium	–	–	+	+	–	+
Swelling of basal infolds	–	–	+	–	–	++
Swelling of mucopolysaccharide masses	+	+	+	+	++	+
Swelling of mitochondria	–	–	+	+	+	++
Disruption to muscle fibres	–	–	–	–	–	–
<i>Changes in Tegumental Cells</i>						
Reduction in number of secretory bodies	–	–	+	–	–	++
Reduction in number and size of Golgi complexes	–	–	+	+	+	+
Swelling of cisternae of GER	–	–	–	+	–	++
Swelling of mitochondria	–	–	+	+	+	++
Spacing between cells	–	–	–	–	++	–
Total	1	1	7	6	7	13

–, No noticeable disruption; +, general/mild disruption; ++, severe disruption; +++, very severe disruption. PB, piperonyl butoxide; NADPH, nicotinamide adenine dinucleotide phosphate; TCBZ, triclabendazole; TCBZ.SO, triclabendazole sulphoxide; GER, granular endoplasmic reticulum.

which is indicative of disruption of the osmoregulatory function of the tegument (Fairweather *et al.* 1999). This swelling would account for the general swelling of the tegument observed in the previous SEM study (Devine *et al.* 2010a). If the basal infolds continued to swell, this would lead to the separation of the syncytium from the underlying basal lamina and the eventual sloughing of the tegument. This progression of changes has been seen in previous studies involving TCBZ.SO (Stitt and Fairweather, 1994; Halferty *et al.* 2009) and other fasciolicides, including clorsulon, closantel, diamphenethide, nitroxynil and compound alpha (Fairweather *et al.* 1986; Skuce *et al.* 1987; Skuce and Fairweather, 1990; Meaney *et al.* 2004, 2007; McConville *et al.* 2008, 2009; McKinsty *et al.* 2007). The blebbing and microvillus-like projections present along the apical plasma membrane are indicative of the accelerated release of damaged surface membrane. The secretory bodies are abnormal and are few in number in the cells; this can be attributed to the lack of Golgi complexes. The GER and mitochondria were disrupted, too. So, the production of secretory bodies is severely affected and this will have a knock-on effect on the ability of the fluke to maintain the integrity of the surface membrane.

With the Cullompton isolate, incubation in TCBZ alone resulted in limited swelling of the basal infolds, mucopolysaccharide masses and mitochondria in the

syncytium (Halferty *et al.* 2009). The decline in the number of secretory bodies in the syncytium could be attributed to the disruption of the Golgi complexes and the reduced numbers of secretory bodies within the tegumental cells (Halferty *et al.* 2009). Co-incubation of PB with TCBZ led to no potentiation of drug action in the Cullompton isolate. While there was greater swelling of the GER with the drug combination, there was no swelling of the basal infolds or reduction in number of secretory bodies in the tegumental cells, as seen following treatment with TCBZ.

Following treatment in TCBZ.SO alone, there was greater disruption to the Cullompton isolate than was seen with TCBZ treatment alone. That is, there was greater swelling of the basal infolds, mitochondria and GER, along with fewer secretory bodies present in the tegumental cells (Halferty *et al.* 2009). When TCBZ.SO was combined with PB, there was little potentiation of drug action: in fact, there was less disruption than with TCBZ.SO alone.

The internal changes in the tegument observed in this study are compatible with the surface changes described in a previous investigation using the same drug and inhibitor incubations (Devine *et al.* 2010a). That is, with the Oberon isolate following incubation in TCBZ.SO and PB, surface swelling and furrowing were observed, while severe swelling of the basal infolds and mucopolysaccharide masses was seen internally. This can be linked to the disruption of the

osmoregulatory system in the syncytium. Energy-dependent ion pumps are located along the apical and basal plasma membranes and their disruption would lead to the influx of water into the fluke and cause the basal infolds to swell (Threadgold and Brennan, 1978; Skuce *et al.* 1987). It would also account for the spacing, or flooding, between cells seen in the subtegumental region. The presence of blebs and microvillus-like projections indicates that the fluke is releasing surface membrane damaged by drug action, in order to facilitate its replacement and repair by fresh membrane, but will be unable to continue to do so. As indicated above, this is probably due to the sharp decrease in the number of secretory bodies in the tegumental system generally and the absence of Golgi complexes in the tegumental cells. The inability to synthesize, produce and transport secretory bodies would have a major impact on the maintenance of the apical plasma membrane and lead to the blebbing seen in this study and in the previous SEM study using PB (Devine *et al.* 2010a).

The combined SEM and TEM results show that the inhibition of drug metabolism by the CYP 450 inhibitor PB has a greater effect in the TCBZ-resistant than TCBZ-susceptible isolates. It is known that the TCBZ-resistant Sligo isolate has a greater ability to metabolize TCBZ to TCBZ.SO than the TCBZ-susceptible Cullompton isolate (Alvarez *et al.* 2005) and TCBZ.SO to TCBZ.SO₂ (Robinson *et al.* 2004). This could possibly be due to the over-expression of the CYP 450 enzyme pathway within the TCBZ-resistant isolates, making them particularly susceptible to enzyme inhibition. It seems as though a similar mechanism is operating in the Oberon flukes. The changes following combination treatment with PB and the FMO inhibitor, MTZ are similar: namely, the severe swelling of the basal infolds and mucopolysaccharide masses and the swelling of the mitochondria and cisternae of GER (Devine *et al.* 2010b; present study). However, there are a number of changes that are more specific to PB, namely, the absence of Golgi complexes, the abnormal secretory bodies and the spacing seen between the tegumental cells. Ketoconazole (KTZ), another CYP 450 inhibitor, is more disruptive than PB, in that it caused the loss of the apical plasma membrane, which would greatly exacerbate drug action. The combined data from the studies published to date indicate that enhanced metabolism is involved in resistance to TCBZ, because inhibition of the FMO and CYP 450 pathways in the fluke seriously affects the ability of TCBZ-resistant flukes to deal with TCBZ and TCBZ.SO and maintain their resistant status (Alvarez *et al.* 2005; Devine *et al.* 2009, 2010a, b, c).

Recently, the co-administration of benzimidazole anthelmintics with metabolic inhibitors has been investigated as a possible strategy to treat drug-resistant parasites. The idea behind this is to extend the active

lifespan of the drug by altering its pharmacokinetic profile and bioavailability, with the aim of increasing its efficacy. Cytochrome P450 enzymes are known to be involved in the metabolism of benzimidazole drugs in mammals (Gottschall *et al.* 1990; Velik *et al.* 2004). Co-administration of PB with fenbendazole has been shown to increase the pharmacokinetic profile of the drug and enhance its nematocidal activity in sheep (Benchaoui and McKellar, 1996) and horses (Sanchez-Bruni *et al.* 2005). Studies with another benzimidazole compound, oxfendazole have also shown that significantly higher plasma concentrations are reached in the presence of PB (McKellar *et al.* 2002; Sanchez *et al.* 2002). More recently, the pharmacokinetics of TCBZ in sheep has been shown to be enhanced by co-administration with PB and KTZ, but not MTZ (Virkel *et al.* 2009). Comparing the impact of the inhibitors on the pharmacokinetics of TCBZ in the host and their action in the fluke, from the evidence obtained to date, the CYP 450 pathway may be a more promising target for drug manipulation than the FMO pathway.

In conclusion, this study has shown that it is possible to alter the susceptibility of a TCBZ-resistant isolate of *F. hepatica* and change it to a more TCBZ-susceptible state by co-treatment with the CYP 450 inhibitor, PB. In doing so, it has reinforced the view that enhanced metabolism is involved in the resistance mechanism. With TCBZ-resistant populations emerging and no new drugs currently in development for *F. hepatica*, co-treatment with metabolic inhibitors may offer one practical solution to modify drug metabolism both within the host and the parasite and maintain the efficacy of the drug. The proof-of-concept data obtained to date with 3 metabolic inhibitors, MTZ, PB and KTZ, suggest that this approach has some potential and needs to be explored further *in vivo*. PB itself may not be used, although it is used as a synergist for the delivery of insecticides in veterinary and human medicine. However, inhibitors with similar action could be adapted or developed for use, in suitable drug + inhibitor combinations.

ACKNOWLEDGEMENTS

This investigation was supported by a DARDNI Postgraduate Studentship to Catherine Devine. It was also partly supported by a grant from the European Union (DELIVER grant, no. FOOD-CT-200X-023025) and by a BBSRC/Defra grant (C00082X/1).

REFERENCES

- Alvarez, L. I., Solana, H. D., Mottier, M. L., Virkel, G. L., Fairweather, I. and Lanusse, C. E. (2005). Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes. *Parasitology* **131**, 501–510.

- Benchaoui, H. A. and McKellar, Q. A.** (1996). Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. *Journal of Pharmacy and Pharmacology* **48**, 753–759.
- Buchanan, J. F., Fairweather, I., Brennan, G. P., Trudgett, A. and Hoey, E. M.** (2003). Surface and internal tegumental changes induced by treatment *in vitro* with the sulphoxide metabolite of albendazole ('Valbazen'). *Parasitology* **126**, 141–153.
- Devine, C., Brennan, G. P., Lanusse, C. E., Alvarez, L. I., Trudgett, A., Hoey, E. and Fairweather, I.** (2009). Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of *Fasciola hepatica*. *Parasitology* **136**, 183–192.
- Devine, C., Brennan, G. P., Lanusse, C. E., Alvarez, L. I., Trudgett, A., Hoey, E. and Fairweather, I.** (2010a). Inhibition of cytochrome P450-mediated metabolism enhances *ex vivo* susceptibility of *Fasciola hepatica* to triclabendazole. *Parasitology* **137**, 871–880.
- Devine, C., Brennan, G. P., Lanusse, C. E., Alvarez, L. I., Trudgett, A., Hoey, E. and Fairweather, I.** (2010b). Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of *Fasciola hepatica*. *Parasitology Research* **106**, 1351–1363.
- Devine, C., Brennan, G. P., Lanusse, C. E., Alvarez, L. I., Trudgett, A., Hoey, E. and Fairweather, I.** (2010c). Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of *Fasciola hepatica* using the metabolic inhibitor ketoconazole. *Parasitology Research* **107**, 337–353.
- Fairweather, I., Anderson, H. R. and Threadgold, L. T.** (1986). *Fasciola hepatica*: tegumental changes induced *in vitro* by the deacetylated (amine) metabolite of diamphenethide. *Experimental Parasitology* **62**, 336–348.
- Fairweather, I., Threadgold, L. T. and Hanna, R. E. B.** (1999). Development of *Fasciola hepatica* in the mammalian host. In *Fasciolosis* (ed. Dalton, J. P.), pp. 47–111. CAB International, Wallingford, Oxon, UK.
- Gottschall, D. W., Theodorides, V. J. and Wang, R.** (1990). The metabolism of benzimidazole anthelmintics. *Parasitology Today* **6**, 115–124.
- Halferty, L., Brennan, G. P., Trudgett, A., Hoey, L. and Fairweather, I.** (2009). The relative activity of triclabendazole metabolites against the liver fluke, *Fasciola hepatica*. *Veterinary Parasitology* **159**, 126–138.
- McConville, M., Brennan, G. P., Flanagan, A., Edgar, H. W. J., McCoy, M., Castillo, R., Hernández-Campos, A. and Fairweather, I.** (2008). Surface and internal tegumental changes in juvenile *Fasciola hepatica* following treatment *in vivo* with the experimental fasciolicide, compound alpha. *Veterinary Parasitology* **153**, 52–64.
- McConville, M., Brennan, G. P., Flanagan, A., Edgar, H. W. J., Castillo, R., Hernández-Campos, A. and Fairweather, I.** (2009). Ultrastructural changes to the tegumental system and the gastrodermal cells in adult *Fasciola hepatica* following *in vivo* treatment with the experimental fasciolicide, compound alpha. *Parasitology* **136**, 665–680.
- McKellar, Q. A., Gokbulut, C., Muzandu, K. and Benchaoui, H.** (2002). Fenbendazole pharmacokinetics, metabolism, and potentiation in horses. *Drug Metabolism and Disposition* **30**, 1230–1239.
- McKinstry, B. D.** (2008). Ultrastructural changes observed in *Fasciola hepatica* following treatment with nitroxylin and triclabendazole, alone and in combination. Ph.D. Thesis, The Queen's University of Belfast, Northern Ireland.
- McKinstry, B., Fairweather, I., Brennan, G. P. and Forbes, A. B.** (2003). *Fasciola hepatica*: tegumental surface alterations following treatment *in vivo* and *in vitro* with nitroxylin ("Trodat"). *Parasitology Research* **91**, 251–263.
- McKinstry, B., Brennan, G. P., Halferty, L., Forbes, A. B. and Fairweather, I.** (2007). Ultrastructural changes induced in the tegument and gut of *Fasciola hepatica* following *in vivo* and *in vitro* drug treatment with nitroxylin (Trodat). *Parasitology Research* **101**, 929–941.
- Meaney, M., Fairweather, I., Brennan, G. P., McDowell, L. S. L. and Forbes, A. B.** (2003). *Fasciola hepatica*: effects of the fasciolicide clorsulon *in vitro* and *in vivo* on the tegumental surface, and a comparison of the effects on young- and old-mature flukes. *Parasitology Research* **91**, 238–250.
- Meaney, M., Fairweather, I., Brennan, G. P. and Forbes, A. B.** (2004). Transmission electron microscope study of the ultrastructural changes induced in the tegument and gut of *Fasciola hepatica* following treatment with clorsulon. *Parasitology Research* **92**, 232–241.
- Meaney, M., Allister, J., McKinstry, B., McLaughlin, K., Brennan, G. P., Forbes, A. B. and Fairweather, I.** (2006). *Fasciola hepatica*: morphological effects of a combination of triclabendazole and clorsulon against mature fluke. *Parasitology Research* **99**, 609–621.
- Meaney, M., Allister, J., McKinstry, B., McLaughlin, K., Brennan, G. P., Forbes, A. B. and Fairweather, I.** (2007). *Fasciola hepatica*: ultrastructural effects of a combination of triclabendazole and clorsulon against mature fluke. *Parasitology Research* **100**, 1091–1104.
- Mottier, L., Virkel, G., Solana, H., Alvarez, L., Salles, J. and Lanusse, C.** (2004). Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidized metabolites into *Fasciola hepatica*. *Xenobiotica* **34**, 1043–1047.
- Robinson, M. W., Lawson, J., Trudgett, A., Hoey, E. M. and Fairweather, I.** (2004). The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant *Fasciola hepatica*. *Parasitology Research* **92**, 205–210.
- Rogan, M. T. and Threadgold, L. T.** (1984). *Fasciola hepatica*: tegumental changes as a result of lectin binding. *Experimental Parasitology* **57**, 248–260.
- Sanchez, S., Small, J., Jones, D. G. and McKellar, Q. A.** (2002). Plasma achiral and chiral pharmacokinetic behavior of intravenous oxfendazole

- co-administered with piperonyl butoxide in sheep. *Journal of Veterinary Pharmacology and Therapeutics* **25**, 7–13.
- Sanchez-Bruni, S. F. S., Fusé, L. A., Moreno, L., Saumell, C. A., Álvarez, L. I., Fiel, C., McKellar, Q. A. and Lanusse, C. E.** (2005). Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses. *Equine Veterinary Journal* **37**, 257–262.
- Skuce, P. J., Anderson, H. R. and Fairweather, I.** (1987). The interaction between the deacetylated (amine) metabolite of diamphenethide (DAMD) and cytochemically demonstrable Na^+/K^+ -ATPase activity in the tegument of *Fasciola hepatica*. *Parasitology Research* **74**, 161–167.
- Skuce, P. J. and Fairweather, I.** (1990). The effect of the hydrogen ionophore closantel upon the pharmacology and ultrastructure of the adult liver fluke *Fasciola hepatica*. *Parasitology Research* **76**, 241–250.
- Stitt, A. W. and Fairweather, I.** (1993). *Fasciola hepatica*: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex). *Parasitology Research* **79**, 529–536.
- Stitt, A. and Fairweather, I.** (1994). The effect of the sulphoxide metabolite of triclabendazole ('Fasinex') on the tegument of mature and immature stages of the liver fluke, *Fasciola hepatica*. *Parasitology* **108**, 555–567.
- Threadgold, L. T. and Brennan, G. P.** (1978). *Fasciola hepatica*: basal infolds and associated vacuoles of the tegument. *Experimental Parasitology* **46**, 300–316.
- Velík, J., Baliharová, V., Fink-Gremmels, J., Bull, S., Lamka, J. and Skálová, L.** (2004). Benzimidazole drugs and modulation of biotransformation enzymes. *Research in Veterinary Science* **76**, 95–108.
- Virkel, G., Lifschitz, A., Sallovitz, J., Ballent, M., Scarcella, S. and Lanusse, C.** (2009). Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep. *Journal of Veterinary Pharmacology and Therapeutics* **32**, 79–86.
- Walker, S. M., McKinstry, B., Boray, J. C., Brennan, G. P., Trudgett, A., Hoey, E. M., Fletcher, H. and Fairweather, I.** (2004). Response of two isolates of *Fasciola hepatica* to treatment with triclabendazole in vivo and in vitro. *Parasitology Research* **94**, 427–438.